On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Primary dyslipidemias
- Structure of lipoproteins
- Physicochemical properties of lipoproteins
- Lipoprotein classes and atherosclerosis
- Autosomal dominant hypercholesterolemia
- Autosomal recessive hypercholesterolemia
- Primary dyslipidemias
- Familial hypercholesterolemia pedigree
- Metabolic abnormality in FH
- The attribute of sex to coronary death
- Typical xanthomas
- Atherosclerosis recognition by Bmode ultrasound
- Thin intima vs. thick intima
- Diagnosis of FH
- Pharmacotherapy
- Mechanism of action of statins
- Increase in the synthesis of hepatic LDL receptors
- Niacin
- Dual inhibition
- Hypolipidemic drug therapy
- Case FH
- Case FH: LDL-c lowering after combined treatment
- FH - current situation
- Tracing FH patients
- Familial combined hyperlipidemia
- FCH prevalence
- 1973 FCH definition
- FCH pedigree
- Lipid and lipoprotein levels in FCH
- Lipoprotein particle size
- Associated CHD risk with an apoB increase
- Insulin resistance in FCH
- Values for prediction of FCH
- Therapy FCH
- Hypertriglyceridemia treatment
- Familial hypertriglyceridemia
- TG levels after treatment
- TG concentration and production
- Triglycerides variation in serum
- Cholesterol and triglycerides elevated
- Familial dysbetalipoproteienemia
- Palmar streaks in FD
- Tubero eruptive xanthomas in FD
- Apolipoprotein E isoforms
- Pedigree of index-patient and family members
- ApoE type and frequencies in the Netherlands
- Cholesterol levels in apoE2/E2
- Aggravating factors
- Lipid values in FD patients
- Reduced penetrance
- Clinical diagnosis
- Secondary dyslipidemias
- Secondary forms of HLP
- Lipemia retinalis
- Appearance of plasma before and after treatment
Topics Covered
- Primary dyslipidemias
- Autosomal dominant and recessive hypercholesterolemia
- Familial hypercholesterolemia
- Familial combined hyperlipidemia
- Familial hypertriglyceridemia
- Familial dysbetalipoproteinemia
- Pharmacotherapy
- Secondary dyslipidemias
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stalenhoef, A. (2008, November 24). Diagnosis and treatment of dyslipidemias [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/MNTX4025.Export Citation (RIS)
Publication History
- Published on November 24, 2008
Financial Disclosures
- Prof. Anton Stalenhoef has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.